Evidence map›Paper›PMID 35116533›Full record

ArticleTranslational cancer research2021

Genetic variations of rs6928 and rs5999521 of

Bo Li, Zheng Lv, Gang Zhao, Youqi Li, Xiaoguang Qiu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Bo Li *Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zheng Lv *Department of Cancer Centre, The First Hospital of Jilin University, Changchun, China.
Gang ZhaoDepartment of Cancer Centre, The First Hospital of Jilin University, Changchun, China.
Youqi LiDepartment of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xiaoguang QiuDepartment of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Beijing Tian Tan Hospital · CNFirst Hospital of Jilin University · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with lung adenocarcinoma with epidermal growth factor receptor (

methodsPatients with pathologically confirmed lung adenocarcinoma from two Hospitals (n=120, discovery cohort; n=213, validation cohort) were enrolled. Magnetic resonance imaging (MRI) was employed for BM follow-up after the completion of planned therapy. Single nucleotide polymorphisms (SNPs) of MAPK pathway genes were tested with blood samples.

resultsAfter adjustment for sex, age, staging, smoking status, surgery, and thoracic radiotherapy, extracellular signal-regulated kinase 2 (

conclusionsIn patients with lung adenocarcinoma,

Indexed as

Brain metastasis (BM)epidermal growth factor receptor (EGFR)mitogen-activated protein kinase (MAPK)non-small cell lung cancer (NSCLC)single nucleotide polymorphism (SNP)

Identifiers

PMID35116533
PMCPMC8798312
OpenAlexW3157488660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.